1. Home
  2. MIRM vs ATS Comparison

MIRM vs ATS Comparison

Compare MIRM & ATS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • ATS
  • Stock Information
  • Founded
  • MIRM 2018
  • ATS 1978
  • Country
  • MIRM United States
  • ATS Canada
  • Employees
  • MIRM N/A
  • ATS N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • ATS
  • Sector
  • MIRM Health Care
  • ATS
  • Exchange
  • MIRM Nasdaq
  • ATS Nasdaq
  • Market Cap
  • MIRM 3.3B
  • ATS 2.7B
  • IPO Year
  • MIRM 2019
  • ATS 2023
  • Fundamental
  • Price
  • MIRM $73.14
  • ATS $28.19
  • Analyst Decision
  • MIRM Strong Buy
  • ATS
  • Analyst Count
  • MIRM 10
  • ATS 0
  • Target Price
  • MIRM $74.20
  • ATS N/A
  • AVG Volume (30 Days)
  • MIRM 679.0K
  • ATS 112.7K
  • Earning Date
  • MIRM 11-11-2025
  • ATS 08-07-2025
  • Dividend Yield
  • MIRM N/A
  • ATS N/A
  • EPS Growth
  • MIRM N/A
  • ATS N/A
  • EPS
  • MIRM N/A
  • ATS N/A
  • Revenue
  • MIRM $429,161,000.00
  • ATS $1,886,061,785.00
  • Revenue This Year
  • MIRM $53.08
  • ATS $17.75
  • Revenue Next Year
  • MIRM $20.45
  • ATS $6.27
  • P/E Ratio
  • MIRM N/A
  • ATS N/A
  • Revenue Growth
  • MIRM 62.33
  • ATS N/A
  • 52 Week Low
  • MIRM $36.86
  • ATS $20.90
  • 52 Week High
  • MIRM $78.10
  • ATS $33.13
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 58.57
  • ATS 52.93
  • Support Level
  • MIRM $73.35
  • ATS $27.00
  • Resistance Level
  • MIRM $74.99
  • ATS $27.62
  • Average True Range (ATR)
  • MIRM 2.37
  • ATS 0.57
  • MACD
  • MIRM -0.94
  • ATS 0.21
  • Stochastic Oscillator
  • MIRM 20.40
  • ATS 72.51

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About ATS ATS Corporation

ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.

Share on Social Networks: